コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ging, and attendant fires and fragmentation (phase III).
2 0.5Mn1.5Ni0.5O4 (Phase II) and Mn1.5Ni0.5O4 (Phase III).
3 velation of the mysterious structure of blue phase III.
4 ere stress occurred during the first part of phase III.
5 optical, and photonic devices based on blue phase III.
6 data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,9
9 imary motor cortex and precerebellar nuclei (phase III) and finally visual cortex in the most severe
10 ous, one-dimensional (1D) polymer at 20 GPa (Phase III); and an extended 3D network above ~35 GPa (Ph
12 tured polymer scaffold of the amorphous blue phase III (BPIII) of cholesteric liquid crystals (LCs),
13 ctive of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and
14 ugs (HAP) have been developed, including the phase III candidate TH-302 (evofosfamide) and the precli
15 nd provide an overview of recently published phase III cardiovascular trials using primary composite
16 ign concept that led to the discovery of the phase III clinical candidate deleobuvir (BI 207127).
18 ients, but these are underrepresented in the phase III clinical studies that established the current
19 the only vaccine platform that has completed Phase III clinical studies, it is imperative to gain a b
21 myocardial salvage index, indicating that a phase III clinical trial assessing intracoronary nitrite
22 ntegration of molecular targeted agents into phase III clinical trial design has lagged in the curati
24 against HIV infection observed in the RV144 phase III clinical trial highlighted the need for furthe
26 2i epitope." IMPORTANCE: Data from the RV144 phase III clinical trial suggested that the presence of
27 antisepsis agent to successfully complete a phase III clinical trial was human recumbent activated p
33 0) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557
34 tematic literature review and identified two phase III clinical trials and a randomized phase II dose
35 than that of (-)-epigallocatechin gallate in Phase III clinical trials and about one order of magnitu
38 ibitors are emerging as anti-cancer drugs in phase III clinical trials for BRCA-deficient tumors.
39 most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated v
40 al agonist of hGPR40 receptor, which reached phase III clinical trials for the potential treatment of
43 inhibitor in clinical testing, with ongoing phase III clinical trials in patients with chronic lymph
45 complete rotavirus genomes collected during phase III clinical trials of RotaTeqTM in Sub-Saharan Af
46 SVR at various post-treatment time points in phase III clinical trials of sofosbuvir (SOF)-containing
48 ation acute coronary syndrome enrolled in 11 phase III clinical trials over 17 years (1994-2010).
53 clinical testing and has progressed through phase III clinical trials, continued efforts are underwa
54 el-targeted TNFalpha derivative currently in phase III clinical trials, substituted for Y-redirected
68 trial predicting an effective or ineffective phase III conclusion, by prediction error, and by concor
69 10), intragastric DB switched the origin of phase III contractions from the stomach to the duodenum
77 rrence of hunger peaks and their relation to phase III contractions, 2) evaluate whether this relatio
81 trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a
82 ibitors, anacetrapib and evacetrapib, are in phase III development, and we attempt to differentiate t
84 national Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled
88 n expression for all targets of marketed and phase III drugs across a diverse collection of normal hu
91 ion, (II) R phase transformation from parent phase, (III) elastic deformation of reoriented martensit
93 ocarcinoma treated within the international, phase III, European Study Group for Pancreatic Cancer-3
94 waits prospective confirmation in the larger phase III FALCON (Fulvestrant and Anastrozole Compared i
96 perties of the practically unobservable blue phase III have eluded scientists for more than a century
97 ric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the
98 stress occurred during the first 40 days of phase III, increasing sugar accumulation, promoted by th
100 hemoradiotherapy arm of the RTOG-9501 trial (Phase III Intergroup Trial of Surgery Followed by Radiot
109 The distribution of enrollment by age in phase III non-ST-segment-elevation acute coronary syndro
111 Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one
116 sex-specific meta-analysis was conducted of phase III or IV randomized trials of potent P2Y12 inhibi
120 enchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying a
121 We obtained individual participant data from phase III placebo-controlled RCTs of therapies for PAH s
125 r data, we have designed a cooperative group phase III prospective, randomized trial of conventional
126 t radiation therapy (RT) in the context of a phase III randomized clinical trial involving localized,
131 ese encouraging results suggest that larger, phase III randomized controlled trials are in order to c
134 this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negativ
135 ancer Institute of Canada SR2 (CAN-NCIC-SR2: Phase III Randomized Study of Pre- vs Postoperative Radi
137 To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in pat
140 ember 2005 and November 2009 in the PETACC-8 phase III randomized trial.Mismatch repair, BRAF V600E,
141 on sensitivity to standard therapies in two phase III randomized trials that represent the developme
143 ndividual patient data was pooled from three phase III randomized, placebo-controlled studies of pirf
145 We report the results of a multicenter, phase III, randomized open-label trial exploring the ben
155 have been shown to provide benefit in IBD in phase III studies by blocking other antiinflammatory pat
158 CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS
160 l compared with docetaxel in two independent phase III studies in previously treated patients with ad
163 but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the tran
170 rongly influenced by results of a randomized phase III study among recurrent patients as well as furt
173 ods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group syst
174 s and Methods This randomized, double-blind, phase III study enrolled patients with histologically co
177 eport the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of li
179 oGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosi
183 e recently published results of a randomized phase III study prompted an update of this guideline.
189 Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of ea
193 oposes ideas for further improvement in blue phase III technology to make it feasible for commerciali
199 ated in an ongoing international, randomized phase III trial comparing alisertib with investigator's
200 10, the patient was enrolled in a randomized phase III trial comparing different lenalidomide-based t
201 prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define
202 randomized, double-blind, placebo-controlled phase III trial conducted in 12 European countries inclu
204 ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to
205 ndomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment
207 mor, and only four randomized trials and one phase III trial have been completed so far, all in the f
208 thout a leukotriene receptor antagonist in a phase III trial in adolescent patients with moderate sym
210 same domains that had at least one completed phase III trial in the same time frame, but failed to re
214 1, a multinational, randomized, double-blind phase III trial of abiraterone acetate plus prednisone v
215 ernational, open-label randomized controlled phase III trial of adjuvant combination chemotherapy com
216 resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic
217 and target population were identified for a phase III trial of IMGN853 monotherapy in patients with
218 y assigned 1:1 in a multicenter, open-label, phase III trial of letrozole (2.5 mg orally per day) wit
219 ction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemother
220 or more controller medications, in the first phase III trial of tiotropium in children with severe sy
222 pective, multicenter, open-label, randomized phase III trial that compared a busulfan-based RIC with
223 ng Patients With Melanoma) was an Intergroup phase III trial that enrolled high-risk patients (stage
224 address this point, we designed a randomized phase III trial to compare rituximab plus cyclophosphami
225 center study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazin
228 Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetux
229 hemotherapy and TME (PROSPECT), a randomized phase III trial to validate this experience, is now open
230 ng results in phase II studies, a randomized phase III trial was designed to assess the efficacy of a
231 CPP FAP-310, a randomized, double-blind, Phase III trial was designed to examine the safety and e
233 lacebo-controlled, randomized, multinational phase III trial, 1,144 patients with human epidermal gro
234 and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal bre
235 ompliant secondary analysis of a prospective phase III trial, adult patients with digital CT images a
238 b (substudy of a larger GSK sponsored global phase III trial, MEA115575) where subjects received mepo
239 d Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) t
253 se II trials were simulated from four actual phase III trials (two positive for OS and two negative f
257 act of TILs in primary TNBCs in two adjuvant phase III trials conducted by the Eastern Cooperative On
260 om 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherc
261 C435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) inf
268 logy of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-
272 se end points in five prospective randomized phase III trials that enrolled a total of 6,081 patients
273 We included patients enrolled onto three phase III trials that randomly assigned patients to nove
274 tcomes, fueling calls for the need for large phase III trials to definitively test this question.
276 gression, and death obtained from randomized phase III trials were used to determine the likelihood o
277 inform go/no-go decisions for proceeding to phase III trials, and appropriate end points in phase II
279 remains the most common primary end point of phase III trials, more trials from the last decade have
281 LDL-C reduction and that, if proven safe in phase III trials, they will be as important to LDL-C con
282 were pooled from four studies, including two phase III trials, with patients who received nivolumab 3
295 b monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665
298 we outline the principal design features of Phase III vector control field studies, highlight major
299 for diabetic macular edema (DME) during the phase III VISTA DME trial were maintained with individua
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。